
Biogen Halts Studies of Closely Watched Alzheimer’s Drug, a Blow to Hopes for New Treatment
Trial failure raises doubts about amyloid as a target for drug development
Trial failure raises doubts about amyloid as a target for drug development
The new drug, Zulresso, can work in days, not the weeks it takes for current treatments
Survival was better than expected with this genetically modified pathogen
This gene therapy for vision loss will initially cost $850,000
The historic treatment’s costs could top $1 million
The experimental treatment will now face review by the agency
Approximately 100,000 people in the U.S. have the disorder
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account